Should You Buy Biontech SE (BNTX) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Buy for a long-term beginner portfolio. At ~$115.6 (down ~3.7% today), BNTX is still in an overall bullish technical structure (short/medium/long MAs stacked positively) and has multiple oncology catalysts expected through 2026. Wall Street sentiment has recently improved with several price-target raises and a notable Goldman upgrade to Buy ($142). While near-term profitability is weak (Q3 net loss), revenue growth and very high gross margin support the longer-term pipeline-driven thesis. With $50k–$100k available and no desire to wait for a ‘perfect’ entry, buying now is justified.
Technical Analysis
Trend/structure: Bullish moving averages (SMA_5 > SMA_20 > SMA_200) suggest the primary trend is up despite today’s pullback.
Momentum: MACD histogram is positive (1.268) but contracting, implying upside momentum is slowing short-term (more consolidation risk than a trend break).
RSI: RSI_6 ~57 is neutral—no clear overbought/oversold signal.
Levels: Pivot support ~114.18 is very close to the current price (~115.62). A clean hold above ~114 supports a continuation attempt toward resistance at ~121.4 (R1) and ~125.86 (R2). If price loses ~114, next notable support is ~106.96 (S1).
Pattern-based projection: Similar-pattern stats imply ~+2.06% next week and ~+15.09% next month (with a small expected dip next day), which aligns with a consolidation-then-push scenario rather than a breakdown.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Analyst Ratings and Price Target Trends
Recent trend: Ratings/targets have generally moved upward. Goldman Sachs upgraded to Buy (PT $142 from $115) on 2026 oncology data unlock potential. Berenberg reiterated Buy and raised PT to $155. H.C. Wainwright raised PT to $140 (Buy). BofA reiterated Buy and raised PT to $134. Morgan Stanley reiterated Overweight and raised PT to $134. UBS stayed Neutral with a modest PT raise to $117.
Wall Street pros: Strong belief in BioNTech’s oncology platform, multiple late-stage programs, and meaningful medium-term catalysts.
Wall Street cons: Ongoing debate about durability of COVID-related revenue and the timing/translation of oncology data into sustained profitability.
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.93 USD with a low forecast of 116 USD and a high forecast of 181 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.93 USD with a low forecast of 116 USD and a high forecast of 181 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 116.160
Current: 116.160
